Cargando…
HER2 Amplification Has no Prognostic Value in Sporadic and Hereditary Ovarian Tumours
Whereas HER2 amplification is a well-known phenomenon in breast tumours, its frequency and clinical importance in ovarian cancer have not been established. The aim of the study was to compare the frequency of HER2 amplification in hereditary (BRCA-positive) and sporadic (BRCA-negative) ovarian tumou...
Autores principales: | Brożek, Izabela, Kardaś, Iwona, Ochman, Karolina, Dębniak, Jarosław, Stukan, Maciej, Ratajska, Magdalena, Morzuch, Lucyna, Emerich, Janusz, Limon, Janusz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401919/ https://www.ncbi.nlm.nih.gov/pubmed/20223002 http://dx.doi.org/10.1186/1897-4287-4-1-39 |
Ejemplares similares
-
Cancer predisposing BARD1 mutations in breast-ovarian cancer families
por: Ratajska, Magdalena, et al.
Publicado: (2012) -
Spectrum and Prevalence of Pathogenic Variants in Ovarian Cancer Susceptibility Genes in a Group of 333 Patients
por: Koczkowska, Magdalena, et al.
Publicado: (2018) -
Mutational analysis of BRCA1/2 in a group of 134 consecutive ovarian cancer patients. Novel and recurrent BRCA1/2 alterations detected by next generation sequencing
por: Ratajska, Magdalena, et al.
Publicado: (2014) -
Analysis of large mutations in BARD1 in patients with breast and/or ovarian cancer: the Polish population as an example
por: Klonowska, Katarzyna, et al.
Publicado: (2015) -
Detection of BRCA1/2 mutations in circulating tumor DNA from patients with ovarian cancer
por: Ratajska, Magdalena, et al.
Publicado: (2017)